scout
Opinion|Videos|October 10, 2024

Key Highlights on POD1UM-303 Presented at ESMO 2024

Panelists discuss how updates from the POD1UM-303/InterAACT2 trial presented at European Society for Medical Oncology Congress (ESMO) 2024 shed light on retifanlimab’s potential role in advancing treatment options for anal cancer patients.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME